Obesity and nonalcoholic fatty liver disease: current perspectives

Raiya Sarwar,1 Nicholas Pierce,2 Sean Koppe3 1Department of Internal Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA; 2University of Medicine and Health Sciences, New York, NY, USA; 3Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarwar R, Pierce N, Koppe S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Non-alcoholic fatty liver disease non-alcoholic steatohepatitis pharmacotherapy clinical trials antifibrotics Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/7fee5a3cccd64043b45fc96d6457a3dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7fee5a3cccd64043b45fc96d6457a3dc
record_format	dspace
spelling	oai:doaj.org-article:7fee5a3cccd64043b45fc96d6457a3dc2021-12-02T01:50:28ZObesity and nonalcoholic fatty liver disease: current perspectives1178-7007https://doaj.org/article/7fee5a3cccd64043b45fc96d6457a3dc2018-09-01T00:00:00Zhttps://www.dovepress.com/obesity-and-nonalcoholic-fatty-liver-disease-current-perspectives-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Raiya Sarwar,1 Nicholas Pierce,2 Sean Koppe3 1Department of Internal Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA; 2University of Medicine and Health Sciences, New York, NY, USA; 3Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA Abstract: Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation for drug development with the focus on metabolic pathways, inflammation, and slowing or reversing fibrosis. There are several agents advancing in clinical trials, and promising results have been seen with drugs that affect hepatic steatosis, inflammation, and fibrosis. This review will provide an overview on NAFLD and some of the mechanisms of disease that are being targeted with pharmacologic agents. Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, pharmacotherapy, clinical trials, antifibroticsSarwar RPierce NKoppe SDove Medical PressarticleNon-alcoholic fatty liver diseasenon-alcoholic steatohepatitispharmacotherapyclinical trialsantifibroticsSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 11, Pp 533-542 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-alcoholic fatty liver disease non-alcoholic steatohepatitis pharmacotherapy clinical trials antifibrotics Specialties of internal medicine RC581-951
spellingShingle	Non-alcoholic fatty liver disease non-alcoholic steatohepatitis pharmacotherapy clinical trials antifibrotics Specialties of internal medicine RC581-951 Sarwar R Pierce N Koppe S Obesity and nonalcoholic fatty liver disease: current perspectives
description	Raiya Sarwar,1 Nicholas Pierce,2 Sean Koppe3 1Department of Internal Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA; 2University of Medicine and Health Sciences, New York, NY, USA; 3Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA Abstract: Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation for drug development with the focus on metabolic pathways, inflammation, and slowing or reversing fibrosis. There are several agents advancing in clinical trials, and promising results have been seen with drugs that affect hepatic steatosis, inflammation, and fibrosis. This review will provide an overview on NAFLD and some of the mechanisms of disease that are being targeted with pharmacologic agents. Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, pharmacotherapy, clinical trials, antifibrotics
format	article
author	Sarwar R Pierce N Koppe S
author_facet	Sarwar R Pierce N Koppe S
author_sort	Sarwar R
title	Obesity and nonalcoholic fatty liver disease: current perspectives
title_short	Obesity and nonalcoholic fatty liver disease: current perspectives
title_full	Obesity and nonalcoholic fatty liver disease: current perspectives
title_fullStr	Obesity and nonalcoholic fatty liver disease: current perspectives
title_full_unstemmed	Obesity and nonalcoholic fatty liver disease: current perspectives
title_sort	obesity and nonalcoholic fatty liver disease: current perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/7fee5a3cccd64043b45fc96d6457a3dc
work_keys_str_mv	AT sarwarr obesityandnonalcoholicfattyliverdiseasecurrentperspectives AT piercen obesityandnonalcoholicfattyliverdiseasecurrentperspectives AT koppes obesityandnonalcoholicfattyliverdiseasecurrentperspectives
_version_	1718402850820718592

Obesity and nonalcoholic fatty liver disease: current perspectives

Ejemplares similares